Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8

Journal of Clinical Endocrinology and Metabolism

Volumn 69, Issue 3, 1989, Pages 654-662

  Nauck, Michael ^a   Schmidt, Wolfgang E ^a   Ebert, Reinhold ^a   Strietzel, Juergen ^a   Cantor, Per ^b   Hoffmann, Georg ^a   Creutzfeldt, Werner ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLECYSTOKININ OCTAPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; PHENYLALANINE;

ADULT; FEMALE; HUMAN; HUMAN EXPERIMENT; INCRETIN; INSULIN RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INFUSIONS, INTRAVENOUS; INSULIN; MALE; METABOLIC CLEARANCE RATE; PHENYLALANINE; REFERENCE VALUES; SINCALIDE;

EID: 0024424884     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem-69-3-654     Document Type: Article

References (41)

1. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37:826-8.
2. Elahi D, Andersen DK, Brown JC, et al. Pancreatic alpha- and beta-cell responses to GIP infusion in normal man. Am J Physiol. 1979;237:E185-91.
3. Sarson DL, Wood SM, Holder D, Bloom SR. The effect of glucose-dependent insulinotropic polypeptide infused at physiological concentrations on the release of insulin in man. Diabetologia. 1982;22:33-6.
4. Sarson DL, Wood SM, Kansal PC, Bloom SR. Glucose-dependent insulinotropic polypeptide augmentation of insulin: physiology or pharmacology? Diabetes. 1984;33:389-93.
5. Jones IR, Owens DR, Moody AJ, Luzio SD, Morris T, Hayes TM. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia. 1987;30:707-12.
6. Krarup T, Saurbrey N, Moody AJ, Kiihl C, Madsbad S. Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. Metabolism. 1987;36:677-82.
7. Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet. 1987;2:1300-4.
8. Fuebl HS, Yiangou Y, Gathei MA, Goebel FD, Bloom SR. Effect of synthetic human glucose-dependent insulinotropic polypeptide insulin secretion in man [Abstract]. Diabetologia. 1988;31:492A.
9. Jörnvall H, Carlquist M, Kwauk S, et al. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP) FEBS Lett. 1981;123:205-10.
10. Moody AJ, Thim L, Valverde I. The isolation and sequencing of human gastric inhibitory peptide (GIP). FEBS Lett. 1984;172: 142-8.
11. Kuzio M, Dryburgh JR, Malloy KM, Brown JC. Radioimmunoassay for gastric inhibitory polypeptide. Gastroenterology. 1974;66:357-64.
12. Sarson DL, Bryant MG, Bloom SR. A radioimmunoassay of gastric inhibitory polypeptide in human plasma. J Endocrinol. 1980;85:487-90.
13. Ebert R, Illmer K, Creutzfeldt W. Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology. 1979;76:515-25.
14. Nauck M, Stockmann F, Schmidt W, Ebert R, Creutzfeldt W. Incretin effect in normal and type 2 diabetic subjects and its relation to the GIP response. Front Horm Res. 1987;16:186-96.
15. Jorde R, Amland PF, Burhol PG, Giercksky KE. What are ‘physiological’ plasma GIP levels in man after intravenous infusion of porcine GIP? Scand J Gastroenterol. 1985;20:268-71.
16. Amland PF, Jorde R, Revhaug A, Myhre ESP, Burhol PG, Giercksky KE. Fasting and postprandial GIP values in pigs, rats, dogs, and man measured with five different GIP antisera. Scand J Gastroenterol. 1984;19:1095-8.
17. Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology. 1978;103:610-5.
18. Fujimoto WY, Williams RH, Ensinck JW. Gastric inhibitory polypeptide, cholecystokinin, and secretin effects on insulin and glucagon secretion by islet cultures. Proc Soc Exp Biol Med. 1979;160:349-53.
19. Ähren B, Hedner P, Lundquist I. Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice. Acta Endocrinol (Copenh). 1983;102:96-102.
20. Fujimoto WY, Ensinck JW, Merchant FW, Williams RH, Smith PH, Johnson DG. Stimulation by gastric inhibitory polypeptide of insulin and glucagon secretion by rat islet cultures. Proc Soc Exp Biol Med. 1978;157:89-93.
21. Yovos JG, O’Dorisio TM, Pappas TN, et al. Effects of amino acids and gastric inhibitory polypeptide on insulin release in dogs. Am J Physiol. 1982;242:E53-8.
22. Nauck M, Strietzel J, Ebert R, Creutzfeldt W. Insulinotropic activity of synthetic human GIP [Abstract]. Diabetologia. 1988;31:525A.
23. Schmidt WE, Siegel EG, Kümmel H, Gallwitz B, Creutzfeldt W. Commercially available preparations of porcine glucose-dependent insulinotropic polypeptides (GIP) contains a biologically inactive GIP-fragment and cholecystokinin-33-39. Endocrinology. 1987;120:835-7.
24. Reimers J, Nauck M, Creutzfeldt W, et al. Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man. Diabetologia. 1988;31:271-80.
25. McGuire EAH, Helderman JH, Tobin JD, Andres R, Berman M. Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol. 1976;41:565-73.
26. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-23.
27. Melani F, Ditschuneit H, Bartelt HM, Friedrich H, Pfeiffer EF. Über die radioimmunologische Bestimmung von Insulin im Blut. Klin Woschenschr. 1965;43:1000-6.
28. Cantor P. Evaluation of a radioimmunoassay for cholecystokinin in human plasma. Scand Lab Clin Invest. 1987;46:213-21.
29. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Peptides. 1984;9:35-46.
30. Krarup T, Holst JJ, Lindorff Larsen K. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol. 1985;249:E195-200.
31. Sarson DL, Hayter RC, Bloom SR. The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man. Eur J Clin Invest. 1982;12:457-61.
32. Tillil H, Shapiro ET, Miller MA, et al. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol. 1988;254:E349-57.
33. Theodorsson-Norheim E. Friedman and Quade tests: Basic computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comp Biol Med. 1987;17:85-99.
34. Schmidt WE, Kümmel H, Creutzfeldt W. Charakterisierung der insulinotropen Aktivität von GIP-Fragmenten [Abstract]. Acta Endocrinol (Stoffw). 1988;9:85.
35. Nauck MA, Hornberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492-8.
36. Krarup T, Holst JJ, Knuhtsen S, Moody AJ, Nielsen OV. Effect of porcine 8000 dalton immunoreactive gastric inhibitory polypeptide on the isolated perfused pig pancreas [Abstract]. Diabetes, 1987;36(Suppl 1):7A.
37. O’Dorisio TM, Sirinek KR, Mazzaferri EL, Cataland S. Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism. 1977;26:651-6.
38. Zawalich WS. Synergistic impact of cholecystokinin and gastric inhibitory polypeptide on the regulation of insulin secretion. Metabolism. 1988;37:778-81.
39. Sandberg E, Ahren B, Tendler, Efendic S. Cholecystokinin-33 potentiates and vasoactive intestinal polypeptide inhibits gastric inhibitory polypeptide-induced insulin secretion in the perfused rat pancreas. Acta Endocrinol (Copenh). 1988;117:545-51.
40. Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA. Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. J Clin Endocrinol Metab. 1987;65:395-401.
41. Verspohl EJ, Ammon HPT. Cholecystokinin (CCK8) regulates glucagon, insulin, and somatostatin secretion from isolated rat pancreatic islets: interactions with glucose. Pfluegers Arch. 1987;410:284-7.